Boule Diagnostics AB (publ) (BOUL.ST)
SEK 7.99
(3.42%)
SEK 7.99
(3.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 128.8 Million SEK | 38.4% |
| 2022 | 93.06 Million SEK | -20.63% |
| 2021 | 117.26 Million SEK | 26.77% |
| 2020 | 92.49 Million SEK | -29.83% |
| 2019 | 131.82 Million SEK | 199.0% |
| 2018 | 44.08 Million SEK | 230.62% |
| 2017 | -33.75 Million SEK | -365.72% |
| 2016 | 12.7 Million SEK | 7.18% |
| 2015 | 11.85 Million SEK | -57.86% |
| 2014 | 28.12 Million SEK | -20.45% |
| 2013 | 35.34 Million SEK | 601.21% |
| 2012 | 5.04 Million SEK | 129.93% |
| 2011 | -16.84 Million SEK | -279.34% |
| 2010 | 9.39 Million SEK | 22.57% |
| 2009 | 7.66 Million SEK | -43.14% |
| 2008 | 13.47 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 137.5 Million SEK | 6.75% |
| 2024 Q3 | 146.7 Million SEK | 8.41% |
| 2024 Q2 | 148.6 Million SEK | 8.07% |
| 2023 Q2 | 138.8 Million SEK | 16.35% |
| 2023 FY | 128.8 Million SEK | 38.4% |
| 2023 Q4 | 128.8 Million SEK | -4.45% |
| 2023 Q3 | 134.8 Million SEK | -2.88% |
| 2023 Q1 | 119.3 Million SEK | 28.19% |
| 2022 Q3 | 205.8 Million SEK | 16.73% |
| 2022 Q1 | 137.8 Million SEK | 17.52% |
| 2022 Q4 | 93.06 Million SEK | -54.78% |
| 2022 FY | 93.06 Million SEK | -20.63% |
| 2022 Q2 | 176.3 Million SEK | 27.94% |
| 2021 Q4 | 117.26 Million SEK | 3.13% |
| 2021 FY | 117.26 Million SEK | 26.77% |
| 2021 Q1 | 95.9 Million SEK | 3.68% |
| 2021 Q3 | 113.7 Million SEK | 0.71% |
| 2021 Q2 | 112.9 Million SEK | 17.73% |
| 2020 Q3 | 101.9 Million SEK | -17.56% |
| 2020 FY | 92.49 Million SEK | -29.83% |
| 2020 Q1 | 128.4 Million SEK | -2.6% |
| 2020 Q2 | 123.6 Million SEK | -3.74% |
| 2020 Q4 | 92.49 Million SEK | -9.23% |
| 2019 Q3 | 135.1 Million SEK | -0.73% |
| 2019 FY | 131.82 Million SEK | 199.0% |
| 2019 Q1 | 127.8 Million SEK | 189.87% |
| 2019 Q2 | 136.1 Million SEK | 6.49% |
| 2019 Q4 | 131.82 Million SEK | -2.42% |
| 2018 Q2 | -5.6 Million SEK | 83.77% |
| 2018 Q4 | 44.08 Million SEK | 838.04% |
| 2018 FY | 44.08 Million SEK | 230.62% |
| 2018 Q1 | -34.5 Million SEK | -2.22% |
| 2018 Q3 | 4.7 Million SEK | 183.93% |
| 2017 Q1 | -4.7 Million SEK | -137.0% |
| 2017 Q4 | -33.75 Million SEK | -181.27% |
| 2017 Q3 | -12 Million SEK | -3100.0% |
| 2017 Q2 | 400 Thousand SEK | 108.51% |
| 2017 FY | -33.75 Million SEK | -365.72% |
| 2016 Q2 | 1.7 Million SEK | 21.43% |
| 2016 FY | 12.7 Million SEK | 7.18% |
| 2016 Q4 | 12.7 Million SEK | -33.15% |
| 2016 Q3 | 19 Million SEK | 1017.65% |
| 2016 Q1 | 1.4 Million SEK | -88.19% |
| 2015 Q2 | 36.2 Million SEK | 16.03% |
| 2015 Q4 | 11.85 Million SEK | -55.45% |
| 2015 Q3 | 26.6 Million SEK | -26.52% |
| 2015 Q1 | 31.2 Million SEK | 10.95% |
| 2015 FY | 11.85 Million SEK | -57.86% |
| 2014 FY | 28.12 Million SEK | -20.45% |
| 2014 Q2 | 24.3 Million SEK | -18.46% |
| 2014 Q4 | 28.12 Million SEK | -14.53% |
| 2014 Q3 | 32.9 Million SEK | 35.39% |
| 2014 Q1 | 29.8 Million SEK | -15.7% |
| 2013 Q2 | 20.05 Million SEK | 58.02% |
| 2013 Q1 | 12.68 Million SEK | 151.7% |
| 2013 FY | 35.34 Million SEK | 601.21% |
| 2013 Q4 | 35.34 Million SEK | 24.24% |
| 2013 Q3 | 28.45 Million SEK | 41.9% |
| 2012 Q2 | -3.99 Million SEK | 70.98% |
| 2012 Q3 | -10.16 Million SEK | -154.55% |
| 2012 Q4 | 5.04 Million SEK | 149.6% |
| 2012 FY | 5.04 Million SEK | 129.93% |
| 2012 Q1 | -13.75 Million SEK | 18.32% |
| 2011 Q1 | 25.2 Million SEK | 168.37% |
| 2011 Q4 | -16.84 Million SEK | -8197.54% |
| 2011 Q3 | -203 Thousand SEK | -100.63% |
| 2011 Q2 | 32.3 Million SEK | 28.18% |
| 2011 FY | -16.84 Million SEK | -279.34% |
| 2010 Q4 | 9.39 Million SEK | 0.0% |
| 2010 FY | 9.39 Million SEK | 22.57% |
| 2009 FY | 7.66 Million SEK | -43.14% |
| 2008 FY | 13.47 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 466.44% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 89.502% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 89.502% |
| Arcoma AB | -1.12 Million SEK | 11518.44% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | -17.217% |
| BICO Group AB (publ) | 927.9 Million SEK | 86.119% |
| CellaVision AB (publ) | -56.94 Million SEK | 326.195% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 965.766% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | 1623.321% |
| C-Rad AB (publ) | -127.6 Million SEK | 200.94% |
| Duearity AB (publ) | 10.23 Million SEK | -1158.919% |
| Dignitana AB (publ) | 13.07 Million SEK | -884.935% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 344.402% |
| Getinge AB (publ) | 5.4 Billion SEK | 97.618% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 467.443% |
| Iconovo AB (publ) | -10.75 Million SEK | 1297.545% |
| Integrum AB (publ) | -10.47 Million SEK | 1329.414% |
| Luxbright AB (publ) | -13.83 Million SEK | 1031.075% |
| Mentice AB (publ) | -49.56 Million SEK | 359.866% |
| OssDsign AB (publ) | -162.78 Million SEK | 179.121% |
| Paxman AB (publ) | -11.41 Million SEK | 1228.735% |
| Promimic AB (publ) | -50.32 Million SEK | 355.947% |
| Qlife Holding AB (publ) | 19.07 Million SEK | -575.406% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 571.38% |
| ScandiDos AB (publ) | -1.53 Million SEK | 8512.802% |
| Sectra AB (publ) | -772.85 Million SEK | 116.666% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 156.772% |
| Senzime AB (publ) | -139.54 Million SEK | 192.303% |
| SpectraCure AB (publ) | -50.23 Million SEK | 356.4% |
| Stille AB | -178.5 Million SEK | 172.155% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 89.511% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 160.004% |